Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer (CARD) (2019)

Peer-Reviewed Study · de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdottir A, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D; CARD Investigators · December 26, 2019

de Wit R et al., 2019-12-26: CARD randomised 255 men who had already received docetaxel and one androgen-receptor inhibitor to cabazitaxel or the alternative inhibitor. Cabazitaxel improved imaging-based progression-free survival (8.0 vs 3.7 months) and overall survival (13.6 vs 11.0 months; HR 0.64), with grade 3+ adverse events in 56.3% vs 52.4%.

The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008).

Abstract (RESULTS)

de Wit R et al., 2019-12-26: CARD randomised 255 men who had already received docetaxel and one androgen-receptor inhibitor to cabazitaxel or the alternative inhibitor. Cabazitaxel improved imaging-based progression-free survival (8.0 vs 3.7 months) and overall survival (13.6 vs 11.0 months; HR 0.64), with grade 3+ adverse events in 56.3% vs 52.4%. Funder: 'Funded by Sanofi'. Conflicts: two co-authors are Sanofi employees (A. Ozatilgan, Sanofi Global Medical Oncology, Cambridge MA; C. Geffriaud-Ricouard, Sanofi Europe Medical Oncology, Paris), listed in the author affiliations. Maker: Sanofi (Jevtana). Comparator: abiraterone or enzalutamide (active alternative), not placebo. Study type: randomized trial.